Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch
Executive Summary
The $50m in sales Merck's Zepatier has posted since its January launch wouldn't seem to explain the first quarter HCV sales decline for its competitors, but Gilead and AbbVie also cite increased discounting, shorter durations of therapy and broader access as factors.